These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 29260038)

  • 21. Sleep improvement with levodopa/carbidopa intestinal gel infusion in Parkinson disease.
    Zibetti M; Rizzone M; Merola A; Angrisano S; Rizzi L; Montanaro E; Cicolin A; Lopiano L
    Acta Neurol Scand; 2013 May; 127(5):e28-32. PubMed ID: 23311399
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of Levodopa-carbidopa Intestinal Gel on Non-motor Symptoms in Patients with Advanced Parkinson's Disease.
    Standaert DG; Rodriguez RL; Slevin JT; Lobatz M; Eaton S; Chatamra K; Facheris MF; Hall C; Sail K; Jalundhwala YJ; Benesh J
    Mov Disord Clin Pract; 2017; 4(6):829-837. PubMed ID: 29242809
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-utility analysis of levodopa carbidopa intestinal gel (Duodopa) in the treatment of advanced Parkinson's disease in patients in Scotland and Wales.
    Kalabina S; Belsey J; Pivonka D; Mohamed B; Thomas C; Paterson B
    J Med Econ; 2019 Mar; 22(3):215-225. PubMed ID: 30484353
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Do we start too late? Insights from the real-world non-interventional BALANCE study on the present use of levodopa/carbidopa intestinal gel in advanced Parkinson's disease in Germany and Switzerland.
    Weiss D; Ebersbach G; Möller JC; Schwarz J; Arlt C; Fritz B; Sensken SC; Eggert K
    Parkinsonism Relat Disord; 2022 Oct; 103():85-91. PubMed ID: 36087571
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Levodopa/carbidopa intestinal gel can improve both motor and non-motor experiences of daily living in Parkinson's disease: An open-label study.
    Juhász A; Aschermann Z; Ács P; Janszky J; Kovács M; Makkos A; Harmat M; Tényi D; Karádi K; Komoly S; Takáts A; Tóth A; Nagy H; Klivényi P; Dibó G; Dézsi L; Zádori D; Annus Á; Vécsei L; Varannai L; Kovács N
    Parkinsonism Relat Disord; 2017 Apr; 37():79-86. PubMed ID: 28185758
    [TBL] [Abstract][Full Text] [Related]  

  • 26. DUOGLOBE: One-Year Outcomes in a Real-World Study of Levodopa Carbidopa Intestinal Gel for Parkinson's Disease.
    Standaert DG; Aldred J; Anca-Herschkovitsch M; Bourgeois P; Cubo E; Davis TL; Iansek R; Kovács N; Pontieri FE; Siddiqui MS; Simu M; Bergmann L; Kukreja P; Robieson WZ; Chaudhuri KR
    Mov Disord Clin Pract; 2021 Oct; 8(7):1061-1074. PubMed ID: 34631942
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Levodopa/carbidopa intestinal gel infusion in advanced Parkinson's disease: a 7-year experience.
    Zibetti M; Merola A; Artusi CA; Rizzi L; Angrisano S; Reggio D; De Angelis C; Rizzone M; Lopiano L
    Eur J Neurol; 2014 Feb; 21(2):312-8. PubMed ID: 24313838
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Developing consensus among movement disorder specialists on clinical indicators for identification and management of advanced Parkinson's disease: a multi-country Delphi-panel approach.
    Antonini A; Stoessl AJ; Kleinman LS; Skalicky AM; Marshall TS; Sail KR; Onuk K; Odin PLA
    Curr Med Res Opin; 2018 Dec; 34(12):2063-2073. PubMed ID: 30016901
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Levodopa infusion in Parkinson's disease: Individual quality of life.
    Ehlers C; Timpka J; Odin P; Honig H
    Acta Neurol Scand; 2020 Sep; 142(3):248-254. PubMed ID: 32383152
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An Observational Study of the Effect of Levodopa-Carbidopa Intestinal Gel on Activities of Daily Living and Quality of Life in Advanced Parkinson's Disease Patients.
    Krüger R; Lingor P; Doskas T; Henselmans JML; Danielsen EH; de Fabregues O; Stefani A; Sensken SC; Parra JC; Onuk K; Yegin A; Antonini A
    Adv Ther; 2017 Jul; 34(7):1741-1752. PubMed ID: 28631218
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A cost-effectiveness analysis of levodopa/carbidopa intestinal gel compared to standard care in late stage Parkinson's disease in the UK.
    Lowin J; Bergman A; Chaudhuri KR; Findley LJ; Roeder C; Schifflers M; Wood E; Morris S
    J Med Econ; 2011; 14(5):584-93. PubMed ID: 21728911
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of Levodopa-Carbidopa Intestinal Gel Compared with Optimized Medical Treatment on Nonmotor Symptoms in Advanced Parkinson's Disease: INSIGHTS Study.
    Chung SJ; Calopa M; Ceravolo MG; Tambasco N; Antonini A; Chaudhuri KR; Robieson WZ; Sánchez-Soliño O; Zadikoff C; Jin M; Barbato LM
    Parkinsons Dis; 2022; 2022():1216975. PubMed ID: 36388237
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term safety and maintenance of efficacy of levodopa-carbidopa intestinal gel: an open-label extension of the double-blind pivotal study in advanced Parkinson's disease patients.
    Slevin JT; Fernandez HH; Zadikoff C; Hall C; Eaton S; Dubow J; Chatamra K; Benesh J
    J Parkinsons Dis; 2015; 5(1):165-74. PubMed ID: 25588353
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Burden of non-motor symptoms in Parkinson's disease patients predicts improvement in quality of life during treatment with levodopa-carbidopa intestinal gel.
    Ray Chaudhuri K; Antonini A; Robieson WZ; Sanchez-Soliño O; Bergmann L; Poewe W;
    Eur J Neurol; 2019 Apr; 26(4):581-e43. PubMed ID: 30353942
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Levodopa-Carbidopa Intestinal Gel Infusion Therapy in Advanced Parkinson's Disease: Single Middle Eastern Center Experience.
    Bohlega S; Abou Al-Shaar H; Alkhairallah T; Al-Ajlan F; Hasan N; Alkahtani K
    Eur Neurol; 2015; 74(5-6):227-36. PubMed ID: 26618531
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Levodopa-carbidopa intestinal gel in advanced Parkinson's: Final results of the GLORIA registry.
    Antonini A; Poewe W; Chaudhuri KR; Jech R; Pickut B; Pirtošek Z; Szasz J; Valldeoriola F; Winkler C; Bergmann L; Yegin A; Onuk K; Barch D; Odin P;
    Parkinsonism Relat Disord; 2017 Dec; 45():13-20. PubMed ID: 29037498
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of Disease Duration in Effectiveness of Treatment with Levodopa-Carbidopa Intestinal Gel and Factors Leading to Discontinuation.
    Regidor I; Santos-García D; Catalán MIJ; Puente V; Valldeoriola F; Grandas F; Mir P; Parra JC; Arbelo JM
    J Parkinsons Dis; 2019; 9(1):173-182. PubMed ID: 30562907
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Continuous infusion of levodopa-carbidopa intestinal gel in Parkinson's disease.
    Guthikonda LN; Lyons KE; Pahwa R
    J Comp Eff Res; 2014 Jul; 3(4):331-3. PubMed ID: 25275230
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Patient and caregiver outcomes with levodopa-carbidopa intestinal gel in advanced Parkinson's disease.
    Valldeoriola F; Catalán MJ; Escamilla-Sevilla F; Freire E; Olivares J; Cubo E; García DS; Calopa M; Martínez-Martín P; Parra JC; Arroyo G; Arbelo JM
    NPJ Parkinsons Dis; 2021 Nov; 7(1):108. PubMed ID: 34848716
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diphasic dyskinesias during levodopa-carbidopa intestinal gel (LCIG) infusion in Parkinson's disease.
    Meloni M; Solla P; Mascia MM; Marrosu F; Cannas A
    Parkinsonism Relat Disord; 2017 Apr; 37():92-96. PubMed ID: 28063683
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.